HUE066879T2 - A Kv3-csatornák modulátorai a fájdalom kezelésére - Google Patents
A Kv3-csatornák modulátorai a fájdalom kezeléséreInfo
- Publication number
- HUE066879T2 HUE066879T2 HUE16813020A HUE16813020A HUE066879T2 HU E066879 T2 HUE066879 T2 HU E066879T2 HU E16813020 A HUE16813020 A HU E16813020A HU E16813020 A HUE16813020 A HU E16813020A HU E066879 T2 HUE066879 T2 HU E066879T2
- Authority
- HU
- Hungary
- Prior art keywords
- modulators
- channels
- treat pain
- pain
- treat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/30—Compounds having groups
- C07C43/315—Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1521751.6A GB201521751D0 (en) | 2015-12-10 | 2015-12-10 | Novel uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE066879T2 true HUE066879T2 (hu) | 2024-09-28 |
Family
ID=55274489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16813020A HUE066879T2 (hu) | 2015-12-10 | 2016-12-09 | A Kv3-csatornák modulátorai a fájdalom kezelésére |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11147813B2 (enExample) |
| EP (1) | EP3386506B1 (enExample) |
| JP (3) | JP7149847B2 (enExample) |
| KR (1) | KR102812887B1 (enExample) |
| CN (2) | CN118267386A (enExample) |
| AU (1) | AU2016367239B2 (enExample) |
| BR (1) | BR112018011700B1 (enExample) |
| CA (1) | CA3005302A1 (enExample) |
| DK (1) | DK3386506T3 (enExample) |
| EA (1) | EA038059B1 (enExample) |
| ES (1) | ES2974902T3 (enExample) |
| FI (1) | FI3386506T3 (enExample) |
| GB (1) | GB201521751D0 (enExample) |
| HR (1) | HRP20240497T1 (enExample) |
| HU (1) | HUE066879T2 (enExample) |
| IL (1) | IL259717B (enExample) |
| MX (1) | MX385578B (enExample) |
| PL (1) | PL3386506T3 (enExample) |
| PT (1) | PT3386506T (enExample) |
| SG (1) | SG11201804123VA (enExample) |
| WO (1) | WO2017098254A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201613163D0 (en) | 2016-07-29 | 2016-09-14 | Autifony Therapeutics Ltd | Novel compounds |
| US20200039970A1 (en) | 2016-12-16 | 2020-02-06 | Autifony Therapeutics Limited | Hydantoin modulators of kv3 channels |
| WO2018220762A1 (ja) * | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
| US12358901B2 (en) * | 2018-10-16 | 2025-07-15 | Autifony Therapeutics Limited | KV3 modulators |
| FI3867247T3 (fi) * | 2018-10-16 | 2024-10-30 | Autifony Therapeutics Ltd | Uusia yhdisteitä |
| AR116898A1 (es) * | 2018-10-30 | 2021-06-23 | H Lundbeck As | DERIVADOS DE ARILSULFONILPIRROLCARBOXAMIDA COMO ACTIVADORES DE CANALES DE POTASIO Kv3 |
| SG11202104374WA (en) | 2018-11-30 | 2021-05-28 | Otsuka Pharma Co Ltd | Heterocyclic compounds for the treatment of epilepsy |
| BR112022013339A2 (pt) | 2020-02-06 | 2022-09-13 | Autifony Therapeutics Ltd | Moduladores de kv3 |
| WO2023017263A1 (en) | 2021-08-10 | 2023-02-16 | Autifony Therapeutics Limited | Potassium channel modulators |
| CN113788741B (zh) * | 2021-09-28 | 2023-12-29 | 大连九信精细化工有限公司 | 一种制备2-环丙基苯酚衍生物的方法 |
| EP4630117A1 (en) | 2022-12-06 | 2025-10-15 | Autifony Therapeutics Limited | Compounds for the treatment of centra nervous system disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102083792A (zh) | 2008-06-06 | 2011-06-01 | Ucb医药有限公司 | 包含环丁氧基的化合物 |
| BR112012015868A2 (pt) * | 2009-12-11 | 2017-06-20 | Autifony Therapeutics Ltd | derivados de imidazolidinadiona |
| WO2012076877A1 (en) | 2010-12-06 | 2012-06-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| EP2718285B1 (en) | 2011-06-07 | 2016-03-16 | Autifony Therapeutics Limited | Hydantoin derivatives as kv3 inhibitors |
| GB201209986D0 (en) | 2012-06-06 | 2012-07-18 | Autifony Therapeutics Ltd | Novel compounds |
| CA2856654C (en) * | 2011-12-06 | 2020-03-31 | Autifony Therapeutics Limited | Hydantoin derivatives useful as kv3 inhibitors |
| CN104334547B (zh) * | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | 作为kv3抑制剂的三唑类 |
| BR112014028718A2 (pt) | 2012-05-22 | 2017-06-27 | Autifony Therapeutics Ltd | derivados de hidantoína como inibidores de kv3 |
| WO2013182851A1 (en) | 2012-06-06 | 2013-12-12 | Autifony Therapeutics Limited | Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required |
| GB201521751D0 (en) | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
| GB201522179D0 (en) | 2015-12-16 | 2016-01-27 | Autifony Therapeutics Ltd | Novel compounds |
-
2015
- 2015-12-10 GB GBGB1521751.6A patent/GB201521751D0/en not_active Ceased
-
2016
- 2016-12-09 ES ES16813020T patent/ES2974902T3/es active Active
- 2016-12-09 BR BR112018011700-5A patent/BR112018011700B1/pt active IP Right Grant
- 2016-12-09 HU HUE16813020A patent/HUE066879T2/hu unknown
- 2016-12-09 PL PL16813020.1T patent/PL3386506T3/pl unknown
- 2016-12-09 CA CA3005302A patent/CA3005302A1/en active Pending
- 2016-12-09 DK DK16813020.1T patent/DK3386506T3/da active
- 2016-12-09 PT PT168130201T patent/PT3386506T/pt unknown
- 2016-12-09 SG SG11201804123VA patent/SG11201804123VA/en unknown
- 2016-12-09 JP JP2018529633A patent/JP7149847B2/ja active Active
- 2016-12-09 CN CN202410102663.8A patent/CN118267386A/zh active Pending
- 2016-12-09 CN CN201680072639.8A patent/CN108472288B/zh active Active
- 2016-12-09 FI FIEP16813020.1T patent/FI3386506T3/fi active
- 2016-12-09 WO PCT/GB2016/053879 patent/WO2017098254A1/en not_active Ceased
- 2016-12-09 MX MX2018007074A patent/MX385578B/es unknown
- 2016-12-09 US US16/060,714 patent/US11147813B2/en active Active
- 2016-12-09 AU AU2016367239A patent/AU2016367239B2/en active Active
- 2016-12-09 EA EA201891377A patent/EA038059B1/ru unknown
- 2016-12-09 EP EP16813020.1A patent/EP3386506B1/en active Active
- 2016-12-09 KR KR1020187017088A patent/KR102812887B1/ko active Active
- 2016-12-09 HR HRP20240497TT patent/HRP20240497T1/hr unknown
-
2018
- 2018-05-30 IL IL259717A patent/IL259717B/en active IP Right Grant
-
2021
- 2021-09-10 US US17/472,493 patent/US11944623B2/en active Active
-
2022
- 2022-06-30 JP JP2022106247A patent/JP2022141699A/ja active Pending
-
2024
- 2024-01-30 US US18/427,639 patent/US20250017925A1/en active Pending
- 2024-09-06 JP JP2024154042A patent/JP2025003958A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259717B (en) | modulators of kv3 channels for pain management | |
| ZA201802663B (en) | Modulators of kras expression | |
| IL259421B (en) | ror - gamma modulators | |
| IL242564A0 (en) | Sodium channel modulators for pain management | |
| ZA201702410B (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| IL258779B (en) | Modulators of sestrin-gator2 interaction and their uses | |
| PL3964213T3 (pl) | Leczenie zaburzeń zachowania | |
| IL259762B (en) | Complement activity modulators | |
| ZA201805861B (en) | TRIFLUOROMETHYL ALCOHOLS AS MODULATORS OF RORyt | |
| SMT202100688T1 (it) | Modulatori di attività del complemento | |
| ZA201705847B (en) | Treatment of pain | |
| EP3271017A4 (en) | Treatment of skin conditions | |
| EP3288616A4 (en) | Reducing pain of skin piercing using vibration | |
| GB201518002D0 (en) | Ketamine for the treatment of somatoform pain disorder | |
| HK40006632A (en) | Treatment of pain | |
| AU2016901912A0 (en) | Treatment of Pain | |
| AU2015900943A0 (en) | Treatment of skin conditions |